血管内皮生长因子受体2(VEGFR2)活性蛋白
Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 编号APB367Hu61
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 97%
- 等电点6.5
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1296 ¥ 3240 ¥ 6480 ¥ 19440 ¥ 48600
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
活性实验
Figure. Cell proliferation of ECV-304 cells inhibit by VEGFR2.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. To test the effect on inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cells were seeded into triplicate wells of 96-well plates at a density of 5,000 cells/well and allowed to attach, replaced with serum-free overnight, then the medium was replaced with 2% serum standard DMEM including 1μg/mL Vascular Endothelial Growth Factor C (VEGFC) and various concentrations of recombinant human VEGFR2. After incubated for 96h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant VEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2 significantly inhibit cell viability of ECV-304.
(A) ECV-304 cells cultured in DMEM, stimulated with 10ng/mL VEGFR2 for 96h;
(B) Unstimulated ECV-304 cells cultured in DMEM for 96h.
Figure. VEGFR2 inhibit VEGF-dependent proliferation of ECV-304 cells.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
APB367Hu61 | 血管内皮生长因子受体2(VEGFR2)活性蛋白 | Cell culture; Activity Assays. |
EPB367Hu61 | 血管内皮生长因子受体2(VEGFR2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB367Hu01 | 血管内皮生长因子受体2(VEGFR2)活性蛋白 | Cell culture; Activity Assays. |
RPB367Hu01 | 血管内皮生长因子受体2(VEGFR2)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB367Hu01 | 血管内皮生长因子受体2(VEGFR2)多克隆抗体 | WB; IHC; ICC; IP. |
LAB367Hu81 | 血管内皮生长因子受体2(VEGFR2)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
LAB367Hu71 | 血管内皮生长因子受体2(VEGFR2)多克隆抗体(生物素标记) | WB; IHC; ICC. |
FAB367Hu51 | 抗血管内皮生长因子受体2(VEGFR2)多克隆抗体(别藻蓝蛋白标记) | FCM |
MAB367Hu23 | 血管内皮生长因子受体2(VEGFR2)单克隆抗体 | WB; IHC; ICC; IP. |
MAB367Hu26 | 血管内皮生长因子受体2(VEGFR2)单克隆抗体 | WB; IHC; ICC; IP. |
RAB367Hu21 | 血管内皮生长因子受体2(VEGFR2)重组抗体 | WB; IF; ICC; IHC; IP; FCM. |
MAB367Hu22 | 血管内皮生长因子受体2(VEGFR2)单克隆抗体 | WB; IHC; ICC; IP. |
MAB367Hu24 | 血管内皮生长因子受体2(VEGFR2)单克隆抗体 | WB; IHC; ICC; IP. |
MAB367Hu21 | 血管内皮生长因子受体2(VEGFR2)单克隆抗体 | WB; IHC; ICC; IP. |
FAB367Hu32 | 抗血管内皮生长因子受体2(VEGFR2)单克隆抗体(别藻蓝蛋白/花青染料cy7标记) | FCM |
FAB367Hu82 | 抗血管内皮生长因子受体2(VEGFR2)单克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
HEB367Hu | 血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEB367Hu | 血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB367Hu | 血管内皮生长因子受体2(VEGFR2)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
KSB367Hu01 | 血管内皮生长因子受体2(VEGFR2)检测试剂盒DIY材料(酶联免疫吸附试验法) | 自己动手制作ELISA试剂盒的主要材料 |
参考文献
杂志 | 参考文献 |
APMIS | Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358] |
Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470] |
Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470] |
Journal of Cellular Physiology | A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells. [pubmed:27925188] |
Regenerative Biomaterials | The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028] |
International Journal of Immunopathology and Pharmacology | VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these … [Pubmed:29985074] |
JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381] |
Journal of Genetic Engineering and Biotechnology | Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells [33523322] |
Mol Cell Biochem | Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy [34324118] |
BMC Nephrol | Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys [Pubmed:35643467] |